
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is positioned favorably because its lead lasofoxifene program is already in an advanced Phase 3 study, with >80% of 600 patients enrolled and completion expected in 4Q26, while top-line results are anticipated in 2H27. The investment case is strengthened by prior Phase 2 ELAINE-2 data showing a competitive 13-month progression-free survival and an attractive safety profile, plus expert support in April 2026 highlighting tolerability as a key differentiator in heavily pretreated ER+/HER2-, ESR1-mutated advanced breast cancer. Financially, the company appears well-funded to execute the program, ending 3Q26 with approximately $32MM in cash, while its ALS asset brelgometon showed favorable Phase 1 safety, tolerability, dose-proportional PK, and CNS penetration, supporting further pipeline optionality.
Bears say
LeonaBio is exposed to substantial clinical, regulatory, and commercialization risk because its pipeline candidates still require additional development before any filing or approval, and the FDA could reject them for data or manufacturing deficiencies. Competitive pressure is also meaningful, since approved disease-modifying and symptomatic agents in Alzheimer’s include generic options that can limit pricing power, while patent or exclusivity challenges to Brelgometon (ATH-1105) and other candidates could weaken future sales. Financially, the company is expected to continue incurring net losses until product approval and likely through the early launch phase, and may need additional capital that could dilute shareholder value.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LeonaBio Inc (LONA) Forecast
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares